Skip to main
TIL

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc is strategically positioned within the biopharmaceutical sector, focusing on developing innovative cell therapies through its CoStAR platform, which could significantly enhance treatment options for various solid tumors. The presence of ITIL-306 in its pipeline highlights the potential for addressing a range of cancers, particularly as this therapy targets tumor-associated antigens prevalent in multiple malignancies. Positive momentum in the broader bispecific class, as indicated by competitive advancements, may provide an advantageous environment for Instil Bio's continued growth and validation of its TIL therapy approach.

Bears say

Instil Bio Inc faces a negative outlook primarily due to the apparent lack of significant improvement in overall survival (OS) curves following recent updates, which has raised concerns among bearish investors regarding the efficacy of its therapies. The company is also exposed to critical risks, including potential delays in clinical advancements and the failure to produce favorable clinical data for key candidates like AXN-2510 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Additionally, there is looming medium- to long-term dilution risk that could further impact investor sentiment and financial stability.

Instil Bio (TIL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.